Pricing Log in Create free account

Immunic, Inc. (IMUX) vs Neumora Therapeutics, Inc. (NMRA)

Immunic, Inc. and Neumora Therapeutics, Inc. are both Biotechnology companies. Immunic, Inc. and Neumora Therapeutics, Inc. are of similar size ($99.9M and $91.5M). Across the 9 metrics below, Immunic, Inc. leads on 8 and Neumora Therapeutics, Inc. on 1.

Valuation

Metric IMUX NMRA Biotechnology median
P/E n/m n/m 10.26
P/S n/m n/m 9.18
P/B 2.46 2.08 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales n/m n/m 8.98
Earnings yield (59.35%) (246.00%) (34.89%)
Free cash flow yield (28.06%) (194.76%) (24.52%)

Profitability

Metric IMUX NMRA Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (138.17%) (187.11%) (50.12%)
Return on assets (101.15%) (121.89%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMUX NMRA Biotechnology median
Revenue growth (TTM) — — 6.26%
EPS growth (last fiscal year) 38.00% 5.23% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric IMUX NMRA Biotechnology median
Debt to equity 0.00 1.19 0.00
Current ratio 5.05 4.50 4.89
Net debt to EBITDA 0.15 0.53 1.01

Dividend

Metric IMUX NMRA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IMUX NMRA Biotechnology median
Market cap 99.88m 91.51m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack